Intuitive Surgical, Inc. Dossier
Qualitative Analysis
Business overview
Intuitive Surgical, Inc. is the pioneer and global technology leader in robotic-assisted, minimally invasive surgery. Founded in 1995, the company designs, manufactures, and markets clinical platforms, most notably the da Vinci Surgical System and the Ion endoluminal system. The da Vinci system enables surgeons to perform complex minimally invasive procedures across general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties. The Ion system extends the company's reach into diagnostic procedures, facilitating minimally invasive peripheral lung biopsies. Intuitive operates on a highly profitable razor-and-blade business model, where approximately 85% of its total revenue is recurring, generated from the sale of instruments, disposable accessories, services, and system leasing.
Research as of 5 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expand deployment of the fifth-generation da Vinci platform and scale Force Feedback instruments and supporting capabilities. Second-quarter 2026 placements included 246 da Vinci 5 systems.
Expected impact: Broaden the next-generation installed base while differentiating the platform through instrument-tip force sensing, updated controls, and an expanding software and instrument ecosystem.
Develop and commercialize da Vinci 5-exclusive digital products combining AI-powered video analysis, objective performance insights, remote surgical collaboration, and console-integrated simulation.
Expected impact: Support surgeon skill development, program optimization, remote mentoring, and deeper integration between customers and the da Vinci 5 ecosystem.
Build adoption in minimally invasive cardiac surgery following FDA clearance for selected cardiac procedures, including mitral-valve repair and internal-mammary-artery mobilization.
Expected impact: Expand the addressable procedure set for da Vinci 5 and provide cardiac surgeons with a minimally invasive alternative for selected procedures.
Continue expanding Ion as a robotic-bronchoscopy platform for minimally invasive peripheral lung biopsy, supported by shape sensing, integrated imaging options, and digital workflow tools.
Expected impact: Increase access to difficult-to-reach peripheral lung nodules and strengthen Intuitive's position across lung-biopsy and thoracic-oncology workflows.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To formally expand direct commercial operations in Southern Europe (Italy, Spain, Portugal, Malta, San Marino, and associated territories), transitioning from a distributor model to direct sales to support customers in a more agile and integrated way.
Financial impact: Adds approximately 250 employees to the Intuitive team and converts major European markets to direct commercial control, expected to accelerate procedure volume and system placement revenue.
Strategic Partnerships
High. The joint venture researches, develops, manufactures, and sells innovative, robotic-assisted catheter-based medical devices (such as the Ion system) in China, providing direct access to one of the world's largest healthcare markets.
Terms: The two parties initially agreed to contribute up to $100 million as required by the joint venture. Intuitive Surgical holds a controlling financial interest in the joint venture, and its results are consolidated into Intuitive's financial statements.